January 24, 2017, Vol 317, No. 4, Pages 333-450
January NaN, 2017
Large HIV Vaccine Trial Launches in South Africa
JAMA. 2017;317(4):350. doi:10.1001/jama.2016.20743
A vaccine that prevents HIV infection may be a step closer to reality with the launch of the large HVTN 702 clinical trial in South Africa late last year. The trial will test the safety and efficacy of a new version of a candidate vaccine studied in the landmark RV144 clinical trial in Thailand.
In 2009, the RV144 vaccine regimen was found to be 31.2% effective at preventing HIV infection over the 3.5-year follow-up period. Now researchers hope a modified version of the vaccine will improve on the modest results of the Thai trial and provide a longer-lasting immune response against the virus that causes AIDS.